New Risk • 6h
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risks High level of debt (59% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Ankündigung • Aug 20
Umicore SA to Report First Half, 2027 Results on Jul 30, 2027 Umicore SA announced that they will report first half, 2027 results on Jul 30, 2027 Ankündigung • Aug 19
Umicore SA to Report Fiscal Year 2026 Final Results on Mar 26, 2027 Umicore SA announced that they will report fiscal year 2026 final results on Mar 26, 2027 Ankündigung • Aug 18
Umicore SA to Report Fiscal Year 2026 Results on Feb 19, 2027 Umicore SA announced that they will report fiscal year 2026 results on Feb 19, 2027 Reported Earnings • Aug 04
First half 2026 earnings released: EPS: €1.00 (vs €0.57 in 1H 2025) First half 2026 results: EPS: €1.00 (up from €0.57 in 1H 2025). Revenue: €13.9b (up 60% from 1H 2025). Net income: €239.8m (up 75% from 1H 2025). Profit margin: 1.7% (up from 1.6% in 1H 2025). The increase in margin was driven by higher revenue. Revenue is expected to fall by 54% p.a. on average during the next 3 years compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • May 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (54% net debt to equity). Share price has been volatile over the past 3 months (8.7% average weekly change). Ankündigung • May 06
Umicore Announces Supervisory Board Appointments Umicore at its ordinary and extraordinary shareholders’ meeting held on April 30th 2026 approved the appointment of Anna Bertona and Benjamin Loh as new Supervisory Board members for a term of 3 years. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €20.24, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 25% over the past three years. Declared Dividend • May 03
Dividend of €0.35 announced Shareholders will receive a dividend of €0.35. Ex-date: 5th May 2026 Payment date: 7th May 2026 Dividend yield will be 2.1%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (31% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. EPS is expected to grow by 8.8% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • May 03
Umicore Sa Announces Chief Financial Officer Changes, Effective August 1, 2026 Umicore SA announced the appointment of Lily Liu as Chief Financial Officer effective August 1, 2026. Mrs. Liu succeeds current CFO Wannes Peferoen who will leave the Company after twenty years of dedicated service. Post handover on August 1st, Mr. Peferoen will serve in a special advisory capacity until February 28, 2027 to ensure a seamless transition. Mrs. Liu joins Umicore from Synthomer, a specialty chemicals company listed on the London Stock Exchange, where she serves as CFO since July 2022. Holding both British and Australian citizenship, she brings more than twenty years of financial leadership experience across the chemicals, manufacturing, and engineering industries. Before her time at Synthomer, Mrs. Liu was CFO at Essentra plc, and previously held CFO positions with Xaar plc and Smiths Detection. She is also a non-executive director and audit committee member at DCC plc. Reported Earnings • Mar 31
Full year 2025 earnings released: EPS: €1.60 (vs €6.15 loss in FY 2024) Full year 2025 results: EPS: €1.60 (up from €6.15 loss in FY 2024). Revenue: €19.4b (up 30% from FY 2024). Net income: €384.5m (up €1.86b from FY 2024). Profit margin: 2.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is expected to fall by 41% p.a. on average during the next 3 years compared to a 9.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Ankündigung • Mar 30
Umicore SA, Annual General Meeting, Apr 30, 2026 Umicore SA, Annual General Meeting, Apr 30, 2026, at 17:00 Romance Standard Time. Reported Earnings • Feb 21
Full year 2025 earnings released: EPS: €1.60 (vs €6.15 loss in FY 2024) Full year 2025 results: EPS: €1.60 (up from €6.15 loss in FY 2024). Revenue: €19.5b (up 32% from FY 2024). Net income: €384.5m (up €1.86b from FY 2024). Profit margin: 2.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is expected to fall by 56% p.a. on average during the next 3 years compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €14.79, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.43 per share. Buy Or Sell Opportunity • Sep 23
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to €13.78. The fair value is estimated to be €11.39, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 41% per annum. Earnings are forecast to grow by 21% per annum over the same time period. Ankündigung • Aug 22
Umicore SA to Report Fiscal Year 2025 Results on Feb 20, 2026 Umicore SA announced that they will report fiscal year 2025 results on Feb 20, 2026 Reported Earnings • Aug 04
First half 2025 earnings released: EPS: €0.57 (vs €6.12 loss in 1H 2024) First half 2025 results: EPS: €0.57 (up from €6.12 loss in 1H 2024). Revenue: €8.69b (up 17% from 1H 2024). Net income: €136.7m (up €1.61b from 1H 2024). Profit margin: 1.6% (up from net loss in 1H 2024). Revenue is expected to fall by 42% p.a. on average during the next 3 years compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. New Risk • Aug 03
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (213% cash payout ratio). Large one-off items impacting financial results. New Risk • Jun 24
New major risk - Revenue and earnings growth Earnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Upcoming Dividend • Apr 21
Upcoming dividend of €0.17 per share Eligible shareholders must have bought the stock before 28 April 2025. Payment date: 30 April 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 6.5%. Within top quartile of British dividend payers (6.2%). Higher than average of industry peers (4.9%). New Risk • Apr 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.1% average weekly change). Reported Earnings • Mar 23
Full year 2024 earnings released: €6.15 loss per share (vs €1.60 profit in FY 2023) Full year 2024 results: €6.15 loss per share (down from €1.60 profit in FY 2023). Revenue: €14.9b (down 19% from FY 2023). Net loss: €1.48b (down 484% from profit in FY 2023). Revenue is expected to fall by 40% p.a. on average during the next 3 years compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 21
Umicore Announces Supervisory Board Changes Umicore at its ordinary and special shareholders’ meetings to be held on April 24, 2025 announced after serving 10 years on Umicore’s Supervisory Board, Mr. Mark Garrett announced that he will not seek to renew his mandate at the upcoming 2025 ordinary shareholders’ meeting. Mr. Laurent Raets, Groupe Bruxelles Lambert (GBL), also announced his intention to step down from the Supervisory Board, after having served 6 years on the Board. Declared Dividend • Feb 24
Final dividend of €0.17 announced Shareholders will receive a dividend of €0.17. Ex-date: 28th April 2025 Payment date: 30th April 2025 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (42% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Ankündigung • Feb 17
Umicore SA, Annual General Meeting, Apr 30, 2025 Umicore SA, Annual General Meeting, Apr 30, 2025. Ankündigung • Feb 15
Umicore Sa Proposes Annual Dividend, Payable on April 30, 2025 Umicore SA's Supervisory Board will propose a gross annual dividend of €0.50 per share for 2024 at the Annual General Meeting on 24 April 2025. This is a reduction from the €0.80 per share paid for 2023. Considering the interim dividend of €0.25 per share paid in August 2024, a gross amount of €0.25 per share will be paid on 30 April 2025, subject to shareholder approval. Based on the closing share price on 31 December 2024 of €9.96, the dividend yield amounts to approximately 5%. Reported Earnings • Feb 15
Full year 2024 earnings released: €6.15 loss per share (vs €1.60 profit in FY 2023) Full year 2024 results: €6.15 loss per share (down from €1.60 profit in FY 2023). Revenue: €14.9b (down 19% from FY 2023). Net loss: €1.48b (down 484% from profit in FY 2023). Revenue is expected to fall by 39% p.a. on average during the next 3 years compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 14
Umicore SA to Report Fiscal Year 2024 Final Results on Mar 21, 2025 Umicore SA announced that they will report fiscal year 2024 final results on Mar 21, 2025 Ankündigung • Feb 01
Umicore SA to Report First Half, 2025 Results on Aug 01, 2025 Umicore SA announced that they will report first half, 2025 results on Aug 01, 2025 Ankündigung • Sep 23
Umicore SA(ENXTBR:UMI) dropped from FTSE All-World Index (USD) Umicore SA(ENXTBR:UMI) dropped from FTSE All-World Index (USD) Upcoming Dividend • Aug 14
Upcoming dividend of €0.17 per share Eligible shareholders must have bought the stock before 19 August 2024. Payment date: 21 August 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 7.0%. Within top quartile of British dividend payers (5.6%). Higher than average of industry peers (3.4%). Declared Dividend • Jul 31
First half dividend of €0.17 announced Shareholders will receive a dividend of €0.17. Ex-date: 19th August 2024 Payment date: 21st August 2024 Dividend yield will be 4.3%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. Reported Earnings • Jul 28
First half 2024 earnings released: €6.12 loss per share (vs €0.93 profit in 1H 2023) First half 2024 results: €6.12 loss per share (down from €0.93 profit in 1H 2023). Revenue: €7.45b (down 26% from 1H 2023). Net loss: €1.47b (down €1.70b from profit in 1H 2023). Revenue is expected to fall by 43% p.a. on average during the next 3 years compared to a 6.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance. New Risk • Jul 28
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 70% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Ankündigung • Jul 26
Umicore SA to Report Fiscal Year 2024 Results on Feb 14, 2025 Umicore SA announced that they will report fiscal year 2024 results on Feb 14, 2025 Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment deteriorates as stock falls 8.8% After last week's 8.8% share price decline to €15.29, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 4x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 68% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.99 per share. New Risk • Jun 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (122% cash payout ratio). Ankündigung • May 16
Umicore Announces Chief Executive Officer Changes Umicore announced the appointment of Bart Sap as Chief Executive Officer, effective May 16th. He will succeed Mathias Miedreich who has decided to step down, in mutual agreement with the Supervisory Board. Bart Sap joined Umicore in 2004 and has been the Executive Vice President Catalysis since March 2021. His nomination is in line with the company's established succession plan. Mathias Miedreich will remain available for advice to Umicore during the next several months. Bart Sap was appointed Executive Vice-President Catalysis on March 1st, 2021. He joined Umicore in 2004 as controller for Cobalt & Specialty Materials and, after successive assignments in Korea and Belgium covering finance, supply and refining of battery raw materials, business development and operations, he became Senior Vice-President for Cobalt & Specialty Materials and Supply at the beginning of 2020. Bart holds a Master’s Degree in Commercial Science from Vlekho in Brussels, Belgium, with majors in Accountancy and Taxation. Upcoming Dividend • Apr 22
Upcoming dividend of €0.39 per share Eligible shareholders must have bought the stock before 29 April 2024. Payment date: 02 May 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of British dividend payers (6.0%). Higher than average of industry peers (2.9%). Ankündigung • Mar 26
Umicore SA Announces Board Changes Mr. Mario Armero announced his intention to step down from the Supervisory Board at the end of this 2024 Annual General Meeting, after having served for a total of 4 years on the Board. The Supervisory Board proposes the appointment of Mr. Frédéric Oudéaas a new Supervisory Board member to replace Mr. Armero for a term of 3 years. Upon his appointment, Mr. Oudéa will also join Umicore's Nomination & Remuneration Committee and its Sustainability Committee. Frédéric Oudéa, a French citizen, is a graduate of the École Polytechnique and the École Nationale d'administration. He spent most of his career in the banking sector, at Société Générale, where he was appointed CEO from 2008 till 2023. He is currently chairman of Sanofi and senior independent director of Capgemini. He is also senior executive advisor to GBL Group. Declared Dividend • Feb 25
Final dividend of €0.39 announced Shareholders will receive a dividend of €0.39. Ex-date: 29th April 2024 Payment date: 1st January 1970 Dividend yield will be 2.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 13% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 18
Full year 2023 earnings released: EPS: €1.60 (vs €2.37 in FY 2022) Full year 2023 results: EPS: €1.60 (down from €2.37 in FY 2022). Revenue: €18.4b (down 28% from FY 2022). Net income: €385.1m (down 32% from FY 2022). Profit margin: 2.1% (in line with FY 2022). Revenue is expected to fall by 37% p.a. on average during the next 3 years compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. New Risk • Jan 17
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.04% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.04% per year for the foreseeable future. Minor Risk Paying a dividend despite having no free cash flows. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €25.91, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 22% over the past three years. Upcoming Dividend • Aug 11
Upcoming dividend of €0.17 per share at 3.0% yield Eligible shareholders must have bought the stock before 18 August 2023. Payment date: 22 August 2023. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of British dividend payers (6.1%). Higher than average of industry peers (2.7%). New Risk • Aug 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.8% per year for the foreseeable future. Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Aug 02
First half 2023 earnings released: EPS: €0.93 (vs €1.29 in 1H 2022) First half 2023 results: EPS: €0.93 (down from €1.29 in 1H 2022). Revenue: €10.0b (down 22% from 1H 2022). Net income: €223.2m (down 28% from 1H 2022). Profit margin: 2.2% (down from 2.4% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is expected to fall by 53% p.a. on average during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Ankündigung • Jul 29
Umicore SA Announces Interim Dividend, Payable on 22 August 2023 Umicore SA announced interim dividend of €0.25 per share, payable on 22 August 2023 with Ex-interim dividend trading date of 18 August 2023 and Record date for the interim dividend of 21 August 2023. Upcoming Dividend • Apr 25
Upcoming dividend of €0.39 per share at 2.7% yield Eligible shareholders must have bought the stock before 02 May 2023. Payment date: 04 May 2023. Payout ratio is a comfortable 34% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.3%). Reported Earnings • Mar 30
Full year 2022 earnings released: EPS: €2.37 (vs €2.57 in FY 2021) Full year 2022 results: EPS: €2.37 (down from €2.57 in FY 2021). Revenue: €25.4b (up 5.7% from FY 2021). Net income: €569.9m (down 7.9% from FY 2021). Profit margin: 2.2% (down from 2.6% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 45% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 2.2%. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 21
Full year 2022 earnings released: EPS: €2.37 (vs €2.57 in FY 2021) Full year 2022 results: EPS: €2.37 (down from €2.57 in FY 2021). Revenue: €25.6b (up 6.5% from FY 2021). Net income: €569.9m (down 7.9% from FY 2021). Profit margin: 2.2% (down from 2.6% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 54% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 1.7%. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Ankündigung • Feb 16
Umicore SA Proposes Gross Annual Dividend for 2022, Payable on 4 May 2023 Umicore SA proposed gross annual dividend for 2022 of €0.80 of which €0.55 to be paid in May 2023, with an interim dividend of €0.25 already paid out in August 2022. Ex-dividend trading date is 2 May 2023. Record date for the dividend is 3 May 2023 and payable date is 4 May 2023. Upcoming Dividend • Aug 12
Upcoming dividend of €0.17 per share Eligible shareholders must have bought the stock before 19 August 2022. Payment date: 23 August 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of British dividend payers (5.1%). Lower than average of industry peers (2.7%). Buying Opportunity • Aug 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.0%. The fair value is estimated to be €46.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to decline by 2.7% per annum. Earnings is forecast to grow by 1.5% per annum over the same time period. Reported Earnings • Aug 03
First half 2022 earnings released: EPS: €1.29 (vs €1.66 in 1H 2021) First half 2022 results: EPS: €1.29 (down from €1.66 in 1H 2021). Revenue: €13.8b (up 9.2% from 1H 2021). Net income: €309.1m (down 23% from 1H 2021). Profit margin: 2.2% (down from 3.2% in 1H 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 83% compared to a 20% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 30
Umicore SA to Report Fiscal Year 2022 Results on Feb 16, 2023 Umicore SA announced that they will report fiscal year 2022 results on Feb 16, 2023 Upcoming Dividend • Apr 27
Upcoming dividend of €0.39 per share Eligible shareholders must have bought the stock before 02 May 2022. Payment date: 04 May 2022. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (4.6%). Lower than average of industry peers (2.7%). Reported Earnings • Mar 28
Full year 2021 earnings released: EPS: €2.57 (vs €0.54 in FY 2020) Full year 2021 results: EPS: €2.57 (up from €0.54 in FY 2020). Revenue: €24.1b (up 16% from FY 2020). Net income: €619.0m (up 374% from FY 2020). Profit margin: 2.6% (up from 0.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 83% compared to a 11% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 28
Full year 2021 earnings released: EPS: €2.57 (vs €0.54 in FY 2020) Full year 2021 results: EPS: €2.57 (up from €0.54 in FY 2020). Revenue: €24.1b (up 16% from FY 2020). Net income: €619.0m (up 374% from FY 2020). Profit margin: 2.6% (up from 0.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 83% compared to a 11% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: €2.57 (up from €0.54 in FY 2020). Revenue: €24.2b (up 17% from FY 2020). Net income: €619.0m (up 374% from FY 2020). Profit margin: 2.6% (up from 0.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Over the next year, revenue is expected to shrink by 83% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €36.65, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 23x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 8.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.51 per share. Upcoming Dividend • Aug 13
Upcoming dividend of €0.17 per share Eligible shareholders must have bought the stock before 20 August 2021. Payment date: 24 August 2021. Trailing yield: 1.3%. Lower than top quartile of British dividend payers (3.8%). Lower than average of industry peers (1.6%). Reported Earnings • Aug 02
First half 2021 earnings released: EPS €1.66 (vs €0.38 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €12.7b (up 27% from 1H 2020). Net income: €400.1m (up 340% from 1H 2020). Profit margin: 3.2% (up from 0.9% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 26
Upcoming dividend of €0.35 per share Eligible shareholders must have bought the stock before 03 May 2021. Payment date: 05 May 2021. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%). Is New 90 Day High Low • Feb 25
New 90-day high: €48.72 The company is up 29% from its price of €37.74 on 26 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €40.25 per share. Reported Earnings • Feb 13
Full year 2020 earnings released: EPS €0.54 (vs €1.20 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €20.7b (up 18% from FY 2019). Net income: €130.5m (down 55% from FY 2019). Profit margin: 0.6% (down from 1.6% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Is New 90 Day High Low • Jan 18
New 90-day high: €46.83 The company is up 35% from its price of €34.68 on 20 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €14.95 per share. Is New 90 Day High Low • Dec 30
New 90-day high: €39.41 The company is up 8.0% from its price of €36.39 on 01 October 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.29 per share. Is New 90 Day High Low • Oct 21
New 90-day low: €34.03 The company is down 25% from its price of €45.28 on 23 July 2020. The British market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.45 per share. Is New 90 Day High Low • Sep 25
New 90-day low: €35.86 The company is down 15% from its price of €42.09 on 26 June 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.42 per share. 
